Genomic analysis of blood and tissue samples from cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on targeted genomic analysis of blood and tissue samples from patients diagnosed with cancer. The study aims to identify genomic alterations that may be linked to treatment options, particularly for rare cancers with poor prognosis. Blood samples will also be collected to analyze circulating DNA and tumor cells. Patients will be monitored for clinical outcomes related to actionable mutations identified through genomic sequencing. The study will also contribute to the development of future cancer models based on tumor genome data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Karnofsky/Lansky performance score \>= 30
* A signed written informed consent
* Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
* Paraffin blocks of the patient's tumor tissue are available and accessible for analysis

Exclusion Criteria:

* Karnofsky/Lansky performance score \< 30
* Life expectancy \< 3 months

Where it's running

• RWJBarnabas Health - Jersey City Medical Center, Jersey City
  Jersey City, New Jersey, United States Recruiting
• Rutgers Cancer Institute of New Jersey
  New Brunswick, New Jersey, United States Recruiting
• Ocean Medical Center
  Brick, New Jersey, United States Completed
• Bayshore Community Hospital
  Holmdel, New Jersey, United States Completed
• Southern Ocean County Medical Center
  Manahawkin, New Jersey, United States Completed
• Morristown Medical Center
  Morristown, New Jersey, United States Completed

Study contacts

• Principal investigator: Shridar Ganesan — Rutgers Cancer Institute of New Jersey
• Study coordinator: Clinical Trials Office
• Phone: 732-235-2465

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.